Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by NattoPharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.

            Lead Product(s): Vitamin K2

            Therapeutic Area: Musculoskeletal Product Name: MenaQ7

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gnosis by Lesaffre

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY